Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of the Calcium Channel Blocker Amlodipine as an Adjuvant Treatment to Iron Chelation for the Prevention of Iron Overload Cardiomyopathy in Patients With Thalassemia

NCT02474420 is registered in ClinicalTrials.gov with Kevin H.M. Kuo, MD, MSc, FRCPC as lead sponsor.

NCT NCT02474420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02474420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of the Calcium Channel Blocker Amlodipine as an Adjuvant Treatment to Iron Chelation for the Prevention of Iron Overload Cardiomyopathy in Patients With Thalassemia
Lead sponsor
Kevin H.M. Kuo, MD, MSc, FRCPC
Phase
Not applicable
Overall status
Unknown status
Start date
June 30, 2015
Completion date
June 30, 2018
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

beta-thalassemia, iron overload